US FTC Probes Planned Allergan-Soliton Merger
Executive Summary
The request for additional records delays the deal, and could indicate that the commission has specific concerns about the merger between the Botox vendor and an aesthetic device manufacturer.
You may also be interested in...
Q2 Dealmaking Statistics: Medtech And Diagnostics M&A And Alliance Activity, April-June 2021
During the second quarter of 2021, device company M&A values reached $2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.4bn.
Illumina Remains Committed To Grail Merger Despite Regulators' Doubts
Illumina insists its proposed $8bn acquisition of Grail, the developer of the Galleri multi-cancer test, would be “pro-competitive.” But antitrust regulators in the US government and European Commission suspect the deal would reduce competition and innovation in the future genomic diagnostics market.
Industry And Investors Ponder Legacy Of Theranos Scandal
What lessons can be learned from the conviction of Theranos founder Elizabeth Holmes, found guilty on four counts of investor fraud in a US court on 4 January?